These procedures include spinal cord stimulation, intrathecal drug delivery, and radiofrequency ablation. They provide alternatives to complicated surgeries and opioid medications for pain relief. Interventional pain procedures use image-guided placement of catheters, neurological stimulation devices, and therapeutic injections to treat pain.
The global Interventional Pain Management Market is estimated to be valued at US$ 8.63 Mn in 2024 and is expected to exhibit a CAGR of 3.6% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing usage of minimally invasive procedures is one of the key drivers of the interventional pain management market growth. These procedures help alleviate pain with less trauma to tissues, shorten recovery times, reduce risks of infection and scarring compared to surgery. As a result, their demand has risen significantly across various therapeutic areas. Furthermore, the rising prevalence of chronic pain disorders like arthritis, back pain and cancer pain is also spurring the adoption of interventional pain management techniques.
Segment Analysis
The Global Interventional Pain Management Market Size is dominated by analgesic infusion devices sub segment. Analgesic infusion devices such as intrathecal drug delivery systems (ITDD) and infusion pumps are widely used for interventional pain management. ITDD and infusion pumps allow direct delivery of pain medications to the intrathecal space near spinal cord or directly into target areas. This ensures localized and immediate delivery of drugs at the site of pain with reduced systemic side effects. As a result, analgesic infusion devices have higher efficiency for interventional chronic and cancer pain management compared to other conventional treatment options.
Key Takeaways
The global interventional pain management market is expected to witness high growth during the forecast period from 2024 to 2031. The global Interventional Pain Management Market is estimated to be valued at US$ 8.63 Mn in 2024 and is expected to exhibit a CAGR of 3.6% over the forecast period 2024 to 2031.
North America region currently dominates the global market owing to high prevalence of chronic pain disorders, rising geriatric population which are highly susceptible to musculoskeletal disorders and favorable reimbursement policies supporting pain management therapies in the region. This is attributed to factors such increasing number of interventional pain procedures performed annually, presence of major players and availability of advanced healthcare facilities in the region. Asia Pacific region is projected to witness highest growth and emerge as the fastest growing regional market. This is attributed to factors such as improving healthcare infrastructure, growing medical tourism industry in the Asia Pacific region.
Key players:
Key players operating in the interventional pain management market are AkzoNobel N.V., CABB Group GmbH, Niacet Corporation, and Denak Co. Ltd. AkzoNobel N.V. dominates the global chloroacetate market owing to its strong production base and global distribution network across major end use industries. CABB Group GmbH is another prominent player in global chloroacetate market with wide product portfolio for various applications.
Get More Insights On This Topic: https://www.newsstatix.com/interventional-pain-management-market-size-share-analysis-2023-2030/
Comments
0 comment